Effect of Glipizide on non-insulin-dependent diabetes mellitus
DOI:
https://doi.org/10.54097/hset.v54i.9760Keywords:
Glipizide; NIDDM; Type 2 diabetes; treatment.Abstract
Type 2 diabetes mellitus, sometimes referred to as non-insulin-dependent diabetes, (NIDDM). The patient was unable to secrete enough insulin, resulting in elevated blood glucose. Complications during a patient's diseases are common in type 2 diabetes patients. Common type 2 diabetes does not have an age or gender difference. Patients with type 2 diabetes or those under treatment are frequently fat and sedentary. Glipizide, a sulfonylurea medication, is prescribed to people with non-insulin-dependent diabetic mellitus. (type 2 diabetes). There are two common types, oral tablets and sustained-release tablets. The common type of oral tablets is fast-acting tablets. Absorption is rapid and the effect is rapid, because oral tablets have a significant effect and may cause short-term hypoglycemia. The body disintegrates the medication and release it. A contributing factor to type 2 diabetes is having high blood glucose levels, as the pancreas produces less insulin, resulting in a residual overall glucose in the blood. These disorders are often caused by genetics or overweight/physical inactivity . The blood glucose levels of patients with type 2 diabetes are greater than those of ordinary healthy individuals since the condition is a chronic metabolic disorder. Glipizide can be used as an insulin secretagogue to stimulate islet β cells to release insulin, thereby increasing plasma insulin concentration. It also serves as an auxiliary hand in diet and exercise. Different regions have different laws for the use of glipizide. Glipizide can be used in combination with other NIDDM drugs in the United States. It can only be used alone or not in the United Kingdom because of the high risk of aggravating hypoglycemia in patients. Patients who have any cardiovascular or renal disease or have a long history do not mind using these drugs. Such agents are likely to worsen the hypoglycemia associated with the disease. Among many drugs, glipizide is one of the most common sulfonylureas and has a moderate price.
Downloads
References
Correa R, Quintanilla Rodriguez BS, Nappe TM. Glipizide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. PubChem Compound Summary for CID 3478, Glipizide, 2023.
Glipizide: Medlineplus Drug Information. MedlinePlus, U.S. National Library of Medicine,
Glipizide. Uses, Interactions, Mechanism of Action | DrugBank Online,
Type 2 Diabetes: Symptoms, Causes, Diagnosis, and Treatment. WebMD, WebMD,
Type 2 Diabetes. Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, 2022.
van de Wiel. Diabetes Mellitus and Alcohol. Diabetes/Metabolism Research and Reviews, U.S. National Library of Medicine
Sun H, Saeedi P, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022,183:109119.
Cheng JWM, Badreldin HA, Patel DK, Bhatt SH. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Curr Med Res Opin, 2017, 33(6):985-992.
Lo C, et.al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev, 2018, 9(9):CD011798.
Nauck MA, et.al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care, 2011, 34(9):2015-22.
Qi, C., Zhou, et.al. Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis. Oncotarget, 2014, 5(20): 9966-9979.
Zhou, et.al. Sentinel Modular Program for Propensity-Score Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. Epidemiology (Cambridge, Mass.),2017, 28(6): 838.
Arjona Ferreira, et.al. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency. Diabetes Care, 2013, 36(5): 1067-1073.
Nauck, M. A.,et.al. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care, 34(9), 2015-2022.
Kautzky-Willer A, et.al. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev. 2016,37(3):278-316.
Diabetes mellitus. Merck Manual Professional Version. Accessed Dec. 7, 2020.
Liu LL, Yi JP, et.al; SEARCH for Diabetes in Youth Study Group. Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study. Diabetes Care, 2009, Suppl 2: S133-40.
Foster RH, Plosker GL. Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics, 2000, 18(3):289-306.
Jie H, Yifei Z, et. al. on behalf of the SPREAD-DIMCAD Investigators; Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients with Type 2 Diabetes and Coronary Artery Disease. Diabetes Care 1, 2013, 36 (5): 1304–1311.
“GLUCOTROL®Clinical Pharmacology (Glipizide).” GLUCOTROL® Clinical Pharmacology (Glipizide) | Pfizer Medical Information - US,
Correa R, Quintanilla Rodriguez BS, Nappe TM. Glipizide.In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
GLUCOTROL®Description (Glipizide). GLUCOTROL® Description (Glipizide)Pfizer Medical Information - US
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







